![Glenn Prestwich](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Glenn Prestwich
Gründer bei
SentrX Animal Care, Inc.
Profil
Glenn D.
Prestwich was the founder of Carbylan Therapeutics, Inc. (founded in 2005) where he served as the Chief Scientific Officer from 2005 to 2010.
He is also the founder of Clear Solutions Biotech, Inc. (founded in 1994) and SentrX Animal Care, Inc. (founded in 2006) where he currently holds the title of Senior Scientific Advisor.
Dr. Prestwich's current job(s) include being the Principal at GlycoMira LLC and a Professor at the University of Utah since 1996.
His former job(s) include being a Director at Brickell Subsidiary, Inc., Chief Scientific Officer at Glycosan BioSystems, Inc., and Chief Scientific Officer at Echelon Biosciences, Inc. (from 1997 to 2003).
Dr. Prestwich obtained a doctorate degree from Stanford University in 1974 and an undergraduate degree from the California Institute of Technology in 1970.
Aktive Positionen von Glenn Prestwich
| Unternehmen | Position | Beginn |
|---|---|---|
University of Utah
 University of Utah Other Consumer ServicesConsumer Services Functions as a College/University | Corporate Officer/Principal | 01.01.1996 |
SentrX Animal Care, Inc.
 SentrX Animal Care, Inc. Pharmaceuticals: MajorHealth Technology Develops and manufactures veterinary products for ophthalmology & wound care | Gründer | 15.02.2010 |
GlycoMira LLC
 GlycoMira LLC Medical/Nursing ServicesHealth Services GlycoMira LLC is a clinical-stage biotechnology company developing mechanism-based oncology therapeutics focused on solid tumors and therapy-resistant cancers with inflammatory origins. The company is based in Salt Lake City, UT. The company's lead drug candidate, GM-1111, is an innate immune system modulator derived from naturally occurring polysaccharides that targets multiple molecular factors in the tumor microenvironment to inhibit innate immune receptor activation, reduce inflammatory signaling, tumor growth, treatment resistance, and cancer stem cell activity. Preclinical studies show GM-1111’s potential to enhance radiation therapy efficacy in head and neck cancers and mitigate radiation-induced oral mucositis. | Corporate Officer/Principal | - |
Ehemalige bekannte Positionen von Glenn Prestwich
| Unternehmen | Position | Ende |
|---|---|---|
Echelon Biosciences, Inc.
 Echelon Biosciences, Inc. BiotechnologyHealth Technology Develops novel research reagents, assays and technology products for drug treatments | Technik-/Wissenschafts-/F&E-Leiter | - |
Clear Solutions Biotech, Inc. | Gründer | 01.01.2001 |
Brickell Subsidiary, Inc.
 Brickell Subsidiary, Inc. Pharmaceuticals: MajorHealth Technology Operates as a clinical-stage pharmaceutical company | Direktor/Vorstandsmitglied | - |
Glycosan BioSystems, Inc.
 Glycosan BioSystems, Inc. Pharmaceuticals: MajorHealth Technology Develops, manufactures, and markets formulations of a hyaluronan-based synthetic extracellular matrix | Technik-/Wissenschafts-/F&E-Leiter | - |
Carbylan Therapeutics, Inc.
 Carbylan Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Engages in development and commercialization of molecule protease inhibitors | Gründer | - |
Ausbildung von Glenn Prestwich
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
91
Beziehungen ersten Grades
10
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 10 |
|---|---|
Carbylan Therapeutics, Inc.
Carbylan Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Engages in development and commercialization of molecule protease inhibitors | Health Technology |
Glycosan BioSystems, Inc.
Glycosan BioSystems, Inc. Pharmaceuticals: MajorHealth Technology Develops, manufactures, and markets formulations of a hyaluronan-based synthetic extracellular matrix | Health Technology |
SentrX Animal Care, Inc.
SentrX Animal Care, Inc. Pharmaceuticals: MajorHealth Technology Develops and manufactures veterinary products for ophthalmology & wound care | Health Technology |
GlycoMira LLC
GlycoMira LLC Medical/Nursing ServicesHealth Services GlycoMira LLC is a clinical-stage biotechnology company developing mechanism-based oncology therapeutics focused on solid tumors and therapy-resistant cancers with inflammatory origins. The company is based in Salt Lake City, UT. The company's lead drug candidate, GM-1111, is an innate immune system modulator derived from naturally occurring polysaccharides that targets multiple molecular factors in the tumor microenvironment to inhibit innate immune receptor activation, reduce inflammatory signaling, tumor growth, treatment resistance, and cancer stem cell activity. Preclinical studies show GM-1111’s potential to enhance radiation therapy efficacy in head and neck cancers and mitigate radiation-induced oral mucositis. | Health Services |
Brickell Subsidiary, Inc.
Brickell Subsidiary, Inc. Pharmaceuticals: MajorHealth Technology Operates as a clinical-stage pharmaceutical company | Health Technology |
Stanford University
 Stanford University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University of Utah
University of Utah Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Echelon Biosciences, Inc.
Echelon Biosciences, Inc. BiotechnologyHealth Technology Develops novel research reagents, assays and technology products for drug treatments | Health Technology |
California Institute of Technology
 California Institute of Technology Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Clear Solutions Biotech, Inc. |
